Skip to main content
SpringerLink
Log in

The effects of age and chronic liver disease on the elimination of temazepam

  • Originals
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

The pharmacokinetics of the newer 1, 4 benzodiazepine temazepam were evaluated in 16 healthy subjects aged 18–92 years and in 15 cirrhotic patients, to ascertain the effect of ageing and liver disease. The data were analysed both by classic two compartment and by non-compartmental methods. The mean elimination half-life in the control subjects was 15.5 h, considerably longer than previous estimates. No correlation was found between age and pharmacokinetic parameters. The cirrhotic group showed no statistically significant difference in the pharmacokinetic parameters nor in the urinary recovery of the dose from the control group. Temazepam plasma protein binding was assessed in a second group of 9 cirrhotics of similar severity to the main group and in matched controls. When these binding data were applied to the mean clearance data, a modest although not statistically significant, reduction in free drug clearance was observed in the cirrhotic group. This study adds further support to the observation that drugs which undergo ether glucuronidation have normal elimination patterns in patients with liver disease. Temazepam may prove to be a useful hypnotic sedative in patients with liver disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Roberts RK, Desmond PV, Schenker S (1979) Drug prescribing in hepatobiliary disease. Drugs 17: 198–212

    Google Scholar 

  2. Klotz U, Avant GR, Hoyumpa A, Schenker S, Wilkinson GR (1975) The effect of age and liver disease on the disposition of diazepam in adult man. J Clin Invest 55: 347–359

    Google Scholar 

  3. Roberts RK, Wilkinson GR, Branch RA, Schenker S (1978) The effect of age and liver disease on the disposition of chlordiazepoxide. Gastroenterology 75: 479–486

    Google Scholar 

  4. Shull HJ, Wilkinson GR, Johnson R, Schenker S (1976) Normal disposition of oxazepam in acute viral hepatitis and cirrhosis. Ann Intern Med 84: 420–425

    Google Scholar 

  5. Kraus JW, Desmond PV, Marshall JP, Johnson RF, Schenker S, Wilkinson GR (1978) Effect of age and liver disease on disposition of lorazepam. Clin Pharmacol Ther 24: 411–419

    Google Scholar 

  6. Greenblatt DJ, Allen MD, Locniskan A, Harmatz J, Shader RI (1979) Lorazepam kinetics in the elderly. Clin Pharmacol Ther 26: 103–113

    Google Scholar 

  7. Greenblatt DJ, Divoll M, Harmatz JS, Shader RI (1981) Oxazepam kinetics — Effect of age and sex. J Pharmacol Exp Ther 30: 475–486

    Google Scholar 

  8. Schwarz HJ (1979) Pharmacokinetics of temazepam in man and several animal species. Br J Clin Pharmacol 8; 23S-29S

    Google Scholar 

  9. Greenblatt DJ, Divoll M, Abernethy DR, Ochs RH, Shader RI (1983) Clinical pharmacokinetics of the newer benzodiazepines. Clin Pharmacokinet 8: 233–252

    Google Scholar 

  10. Ghabrial H, Harman PJ, Mashford ML (1986) An HPLC assay for temazepam, oxazepam and their glucuronides in plasma, bile and urine. J Chromatogr (in press)

  11. Yamaoka K, Nakagawa T, Uno T (1978) Statistical moments in pharmacokinetics. J Pharmacokinet Biopharm 6: 547–558

    Google Scholar 

  12. Benet LZ, Galeazzi RL (1979) Non-compartmental determination of the steady state volume of distribution. J Pharm Sci 68: 1071–1974

    Google Scholar 

  13. Perrier D, Mayersohn M (1982) Noncompartmental determination of the steady state volume of distribution for any mode of administration. J Pharm Sci 71: 372–373

    Google Scholar 

  14. Conn HQ (1981) A peek at the Child-Turcotte classification. Hepatology 1: 673–676

    Google Scholar 

  15. Fuccella LM, Tosolini G, Moro E, Tamassia V (1972) Study of the physiological availability of temazepam in man. Int J Clin Pharmacol Ther Toxicol 6: 303–309

    Google Scholar 

  16. Fuccella LM, Bolcioni G, Tamassia V, Ferrario L, Tognoni G (1977) Human pharmacokinetics and bioavailability of temazepam administered in soft gelatin capsules. Eur J Clin Pharmacol 12: 383–386

    Google Scholar 

  17. Fuccella LM (1979) Bioavailability of temazepam in soft gelatin capsules. Br J Clin Pharmacol 8: 31S-35S

    Google Scholar 

  18. Bittencourt P, Richens A, Roseland PA, Wick JFC, Latham AN (1979) Pharmacokinetics of the hypnotic benzodiazepine temazepam. Br J Clin Pharmacol 8: 37S-38S

    Google Scholar 

  19. Divoll M, Greenblatt DJ, Harmatz JS, Shader RI (1981) Effect of age and gender on the disposition of temazepam. J Pharm Sci 70: 1104–1107

    Google Scholar 

  20. Jochemsen R, van Boxtel CJ, Hermans J, Breimer DD (1983) Kinetics of five benzodiazepine hypnotics in healthy subjects. Clin Pharmacol Ther 34: 42–47

    Google Scholar 

  21. Greenblatt DJ, Allen MD, Harmatz JS, Shader RI (1980) Diazepam disposition determinants. Clin Pharmacol Ther 27: 301–312

    Google Scholar 

  22. Allen MD, Greenblatt DJ, Harmatz JS, Shader RI (1980) Desmethyldiazepam kinetics in the elderly after oral prazepam. Clin Pharmacol Ther 28: 196–202

    Google Scholar 

  23. Azzollini F, Gazzaniga A, Lodola E, Natangelo R (1972) Elimination of chloramphenicol and thiamphenicol in subjects with cirrhosis of the liver. Int J Clin Pharmacol Ther Toxicol 6: 130–134

    Google Scholar 

  24. Kunin CM, Glazko AJ, Finland M (1959) Persistence of antibiotics in the blood of patients with acute renal failure II: Chloramphenicol and its metabolic product in the blood of patients with severe renal or hepatic cirrhosis. J Clin Invest 38: 1498–1508

    Google Scholar 

  25. Patwardhan RV, Johnson RF, Hoyumpa A, Sheehan JJ, Desmond PV, Wilkinson GR, Branch RA, Schenker S (1981) Normal metabolism of morphine in cirrhosis. Gastroenterology 81: 1006–1011

    Google Scholar 

  26. Gerkens JF, Desmond PV, Schenker S, Branch RA (1981) Hepatic and extrahepatic glucuronidation of lorazepam in the dog. Hepatology 1: 329–335

    Google Scholar 

  27. Jones DP (1981) Hypoxia and drug metabolism. Biochem Pharmacol 30: 1019–1023

    Google Scholar 

  28. Branch RA, Cotham R, Johnson R, Porter J, Desmond PV, Schenker S (1983) Periportal localization of lorazepam glucuronidation in the isolated perfused rat liver. J Lab Clin Med 102: 805–812

    Google Scholar 

  29. Desmond PV, James R, Schenker S, Gerkens JF, Branch RA (1981) Preservation of glucuronidation in carbon tetrachloride induced acute liver injury in rats. Biochem Pharmacol 30: 993–999

    Google Scholar 

  30. Gregus Z, Watkins JB, Thompson TN, Klaassen CD (1982) Resistance of some phase II biotransformation pathways to hepatotoxins. J Pharmacol Exp Ther 222: 471–479

    Google Scholar 

  31. James R, Desmond PV, Kupfer A, Schenker S, Branch RA (1981) The differential localization of various drug metabolising systems within the rat liver lobule as determined by the hepatotoxins allyl alcohol, carbon tetrachloride and bromobenzene. J Pharmacol Exp Ther 217: 127–132

    Google Scholar 

  32. Witaasek F, Bircher J, Huguenin P, Preisig R (1983) Abnormal glucuronidation of zomepirac in patients with cirrhosis of the liver. Hepatology 3: 415–422

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Melbourne Department of Medicine, and the Gastroenterology Unit, St. Vincent's Hospital, 3065, Fitzroy, Australia

    H. Ghabrial, P. V. Desmond, K. J. R. Watson, A. J. Gijsbers, P. J. Harman, K. J. Breen & M. L. Mashford

Authors
  1. H. Ghabrial
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. V. Desmond
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K. J. R. Watson
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. J. Gijsbers
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P. J. Harman
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. K. J. Breen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M. L. Mashford
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ghabrial, H., Desmond, P.V., Watson, K.J.R. et al. The effects of age and chronic liver disease on the elimination of temazepam. Eur J Clin Pharmacol 30, 93–97 (1986). https://doi.org/10.1007/BF00614203

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00614203

Key words

Search

Navigation